<DOC>
	<DOCNO>NCT00197561</DOCNO>
	<brief_summary>The purpose study determine whether oral administration daily selenium supplement HIV-1 positive pregnant woman : enhances immune status reduces HIV-1 viral load six month postpartum , reduces risk low genital shed HIV-1 infected cell 36 week gestation , reduces risk mastitis six week postpartum , compare placebo .</brief_summary>
	<brief_title>Partnership Nutrition HIV/AIDS Research Tanzania : Exploratory Research Study Selenium HIV Infection</brief_title>
	<detailed_description>We recruit pregnant woman infect HIV assign receive selenium placebo . All woman give standard prenatal care , include nevirapine prevention mother-to-child transmission prenatal multivitamin supplement . We examine effect selenium supplement intermediate outcome predictive risk transmission HIV disease progression .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Pregnancy Complications</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>HIV1 Infected woman 12 27 week gestation Women clinical AIDS define accord WHO Criteria</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>HIV</keyword>
	<keyword>Selenium</keyword>
	<keyword>Nutrition</keyword>
	<keyword>Women</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Tanzania</keyword>
	<keyword>Maternal child health outcome</keyword>
	<keyword>HIV/AIDS</keyword>
	<keyword>Pregnancy Outcome</keyword>
</DOC>